BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ignatov T, Gorbunow F, Eggemann H, Ortmann O, Ignatov A. Loss of HER2 after HER2-targeted treatment. Breast Cancer Res Treat 2019;175:401-8. [DOI: 10.1007/s10549-019-05173-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol 2021;5:28. [PMID: 33772089 DOI: 10.1038/s41698-021-00165-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tobias J, Drinić M, Högler S, Ambroz K, Baier K, Kodajova P, Tomasich E, Berghoff AS, Schmid A, Garner-spitzer E, Kenner L, Kundi M, Zielinski CC, Wiedermann U. Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model. Translational Oncology 2022;19:101378. [DOI: 10.1016/j.tranon.2022.101378] [Reference Citation Analysis]
3 Li F, Ju Q, Gao C, Li J, Wang X, Yan M, Zhang L, Huang M, Long Q, Jin X, Li N. Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab. Front Oncol 2022;12:819818. [DOI: 10.3389/fonc.2022.819818] [Reference Citation Analysis]
4 Furumaya C, Martinez-Sanz P, Bouti P, Kuijpers TW, Matlung HL. Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance. Front Immunol 2020;11:2100. [PMID: 32983165 DOI: 10.3389/fimmu.2020.02100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
6 Shaaban AM, Provenzano E. Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications. Pathobiology 2022;:1-12. [PMID: 35636403 DOI: 10.1159/000521880] [Reference Citation Analysis]
7 Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer Vaccines, Adjuvants, and Delivery Systems. Front Immunol 2021;12:627932. [PMID: 33859638 DOI: 10.3389/fimmu.2021.627932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Rey-Vargas L, Mejía-Henao JC, Sanabria-Salas MC, Serrano-Gomez SJ. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer 2020;20:675. [PMID: 32682413 DOI: 10.1186/s12885-020-07179-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Mohamed AA, Lau DK, Chau I. HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews 2022;105:102363. [DOI: 10.1016/j.ctrv.2022.102363] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 He L, Araj E, Peng Y. HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. Curr Oncol 2021;28:1608-17. [PMID: 33923191 DOI: 10.3390/curroncol28030150] [Reference Citation Analysis]
11 Grassini D, Cascardi E, Sarotto I, Annaratone L, Sapino A, Berrino E, Marchiò C. Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives. Pathobiology 2022;:1-19. [PMID: 35500561 DOI: 10.1159/000524227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wetzel CL, Sutton TL, Gardiner S, Farinola M, Johnson N, Garreau JR. Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. J Surg Oncol 2021. [PMID: 34416025 DOI: 10.1002/jso.26646] [Reference Citation Analysis]
13 Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33-48. [PMID: 31548601 DOI: 10.1038/s41571-019-0268-3] [Cited by in Crossref: 123] [Cited by in F6Publishing: 126] [Article Influence: 41.0] [Reference Citation Analysis]
14 Oh D, Bang Y. HER2-targeted therapies — a role beyond breast cancer. Nat Rev Clin Oncol 2020;17:33-48. [DOI: 10.1038/s41571-019-0268-3] [Reference Citation Analysis]
15 Brentville VA, Metheringham RL, Daniels I, Atabani S, Symonds P, Cook KW, Vankemmelbeke M, Choudhury R, Vaghela P, Gijon M, Meiners G, Krebber WJ, Melief CJM, Durrant LG. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses. J Immunother Cancer 2020;8:e000560. [PMID: 32561639 DOI: 10.1136/jitc-2020-000560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
16 Loria R, Vici P, Di Lisa FS, Soddu S, Maugeri-saccà M, Bon G. Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Front Oncol 2022;12:877380. [DOI: 10.3389/fonc.2022.877380] [Reference Citation Analysis]
17 Strizova Z, Vachtenheim J Jr, Bartunkova J. The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression. Breast Cancer Res Treat 2019;178:247-8. [PMID: 31377896 DOI: 10.1007/s10549-019-05386-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]